No abstract

No abstract

duration (4 months common vs 6 months uncommon/complex mutations). Notably, 60% of patients with a common mutation treated with other 1L systemic therapies went on to receive a 2L EGFR TKI. Conclusion: Uncommon/complex mutations were present in over 20% of aNSCLC patients with any EGFR mutations. Increased overall survival and 1L treatment duration with EGFR TKI therapy were observed in patients with common mutation subtypes vs. uncommon/complex mutation subtypes.

No abstract